Payers: Lynparza Coverage Will Be at Parity With Other Second-Line Prostate Cancer Drugs
AstraZeneca and Merck & Co., Inc. released positive results of Lynparza’s Phase III PROfound trial last August. Shortly thereafter, from Sept. 3, 2019, to Oct. 7, 2019, Zitter Insights polled 51 commercial payers with 158.4 million covered lives about how they were likely to manage the therapy.
Commercial payers with 60% of covered lives said they were more likely than unlikely and significantly likely to manage Lynparza at parity with other drugs in the second-line treatment of metastatic castration- resistant prostate cancer (see chart below). The same percentage of payers said they were neither likely nor unlikely to cover it over all other therapies.
Related Posts

January 12
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
January 12
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE
January 12